Celiac Disease Pipeline Analysis Report 2026

Report Coverage

The Celiac Disease Pipeline Analysis Report by Expert Market Research gives comprehensive insights into celiac disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for celiac disease. The celiac disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The celiac disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with celiac disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to celiac disease.

Read more about this report - Request a Free Sample

Celiac Disease Pipeline Outlook

Celiac Disease is a chronic autoimmune disorder triggered by the ingestion of gluten, a protein found in wheat, barley, and rye. It damages the small intestine’s lining, impairing nutrient absorption and causing symptoms like diarrhea, bloating, fatigue, anemia, and weight loss. Genetic predisposition and immune system dysregulation contribute to disease onset and severity.

Celiac disease treatment primarily involves a strict, lifelong gluten-free diet to prevent intestinal damage and alleviate symptoms. Adjunct therapies are under investigation to manage persistent symptoms despite dietary adherence. In May 2025, Celiac Disease treatment TEV-53408, an anti-IL-15 monoclonal antibody by Teva Pharmaceutical Industries, received FDA fast-track designation. The drug works by inhibiting interleukin-15 to reduce gluten-induced intestinal injury, offering a promising therapy for patients with unmet medical needs.

Celiac Disease Epidemiology

As per Gabriel Alejandro de Diego et al., 2024, Celiac Disease (CeD) affects approximately 1–2% of the global population, though true incidence and prevalence are difficult to determine due to its variable manifestations. Epidemiological studies in Argentina show a pediatric prevalence of 1.26% and an adult prevalence of 0.6%, with higher rates in women (0.8%) than men (0.4%), affecting over 400,000 people. According to Beyond Celiac, up to 83% of CeD cases in the United States remain undiagnosed or misdiagnosed, with one in 133 Americans affected. Edna Keeney et al., 2024, report that around 1% of the United Kingdom population is affected, with only 30% diagnosed. These trends highlight the urgent need for effective therapeutic developments and early diagnostic solutions.

Celiac Disease – Pipeline Therapeutic Assessment

Celiac Disease Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II holds 42%, covering a major share of the total celiac disease clinical trials. It is followed by phase I at 25%. The phase IV remains at 17% and early phase I at 8%. This balanced segmentation reflects strong mid‑stage momentum, which could spur faster approvals, enhance innovation, and expand treatment options in the celiac disease market.

Celiac Disease Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the celiac disease pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The celiac disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for celiac disease. Enzyme-targeted therapies are emerging in the celiac disease drug pipeline to manage gluten-induced intestinal damage. For instance, ZED1227, a transglutaminase 2 inhibitor, is under investigation. It works by blocking the TG2 enzyme, preventing harmful changes to gluten and reducing T cell-mediated duodenal inflammation. Early clinical trials show promising results, particularly in patients with specific HLA-DQ genetic profiles.

Celiac Disease Clinical Trials – Key Players

The EMR report for the celiac disease pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed celiac disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in celiac disease clinical trials:

• Forte Biosciences, Inc.
• Teva Branded Pharmaceutical Products R&D LLC
• Barinthus Biotherapeutics
• Pfizer
• Takeda
• Mozart Therapeutics Australia Pty Ltd.
• Kanyos Bio, Inc.
• Igy Inc.
• Topas Therapeutics GmbH
• Merck Sharp & Dohme LLC
• Protagonist Therapeutics, Inc.
• Alvine Pharmaceuticals Inc.

Celiac Disease – Emerging Drugs Profile

Key Questions Answered in the Celiac Disease Pipeline Insight Report

• Which companies/institutions are leading the celiac disease drug development?
• Which company is leading the celiac disease pipeline development activities?
• What is the current celiac disease commercial assessment?
• What are the opportunities and challenges present in the celiac disease pipeline landscape?
• What is the efficacy and safety profile of celiac disease pipeline drugs?
• Which company is conducting major trials for celiac disease drugs?
• Which companies/institutions are involved in celiac disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in celiac disease?

Reasons To Buy This Report

The Celiac Disease Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for celiac disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into celiac disease collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Celiac Disease (CD) Epidemiology Forecast

Gluten Free Products Market